Abstract. Recently somatostatin analogues were successfully used to control insulin-induced hypoglycemia in patients with insulinoma. We observed a transient decrease 
successfully used to control insulin-induced hypo¬ glycemia in patients with insulinoma (1) (2) (3) (4) (5) .
Important advantages of long-acting somatos¬ tatin analogues compared with native somatos¬ tatin are their prolonged half life, the possibility of subcutaneous administration, and the lack of a re¬ bound increase in insulin levels after discontinu¬ ing treatment. Furthermore, no clinically import¬ ant adverse effects during short-term therapy have been reported in insulinoma patients (1) (2) (3) (4) (5) (6) . We (Fig. 1, open circles) .
As stated above, additional studies were per¬ formed in patient B (Fig. 2) CLOCK TIME (am) 10 12 CLOCKTIME(a.m) 10 12 Fig (8) (9) (10) (11) and octreotide (12, 13) (18) . Gluca¬ gon levels averaged approximately 110 ng/1 during the infusion compared with approximately 30 ng/1 at baseline. The resultant ratio of 3.7 is higher than the reported portal: peripheral venous ratio of 2.7 and it therefore appears unlikely that portal ven¬ ous glucagon levels during the replacement infu¬ sion were too low. The absence of a rapid and steep rise in glucose levels argues against the possibility that the glucagon levels were unphysiologically high.
Glucagon influences blood glucose mainly by regulation of hepatic glucose production (19) . In¬ deed it appears that the octreotide-associated changes in blood glucose levels observed can be explained by rapid changes in hepatic glucose pro¬ duction, assuming a relatively constant rate of pe¬ ripheral glucose utilisation. In addition, chronic hyperglucagonemia may increase intestinal carbo¬ hydrate absorption (20) . For two reasons, however, this cannot explain the observed changes in blood glucose. Firstly, glucagon replacement cannot reverse somatostatin-induced reductions of nutrient absorption (8 (25, 26) and octreotide (27) have been shown to be able to suppress the gluca¬ gon and GH, but not the cortisol or catecholamine response to insulin-induced hypoglycemia. The re¬ sults of our study are in agreement with these re¬ ports (25) (26) (27) 
